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Role of CD82 in prevention of prostate cancer metastasis*

Bikash Mishra
McNair Scholar

Suganthi Sridhar
Faculty Mentor

Prostate cancer is one of the most
commonly diagnosed forms of cancer
in males; it is the second most frequent
cause of cancer related death in the United
States. A diagnosis of a malignant tumor
is divided into four stages. During stage
one, the cancer cells remains localized
within the tumor itself. As the tumor
grow and progress into stage two, cells
break through the basement membrane
guarding the surrounding tissue, and in
stage three they migrated to the nearest
lymph nodes. Once the cancer has
invaded the lymph nodes then it has
free access to the bloodstream, and the
prognosis significantly diminishes. Cancer
is deadliest during stage 4 because at
this stage, cancerous cells can be found
throughout the body system, making it
nearly impossible to combat. Stages 1-3
is also considered a primary stage, and
during this stage the cancer is confined to
the prostate gland only, so it is treatable.
In the metastatic stage, the cancer spreads
beyond the prostate which increases the
mortality rate.

progress. Loss or low expression of CD82
has been observed in many invasive and
metastatic tumors, which means loss
of CD82 is correlated with changes in
cytoskeleton structure of the cells. Some
of the changes may allow cells to move
freely (no longer adhering) and be invasive
as well as help with cell migration. The
proposed research looked into how the
reintroduction of CD82 in metastatic
prostate cancer would prevent cell motility
and affect cell signalling and cell adhesion.
Understanding the mechanism by which
re-introduction of CD82 affect cell
signalling, cell adhesion and cytoskeleton
structure rearrangement propose a greater
potential for controlling the mechanism
of metastasis. If metastasis could be
controlled, it would provide a huge step
towards preventing metastatic cancer.
*This scholar and faculty mentor have
requested that only an abstract be
published.

One factor that has been identified that
leads to metastasis is the activation of
the c-Met signalling pathway. The c-Met
signalling pathway has been implicated in
many functions including metastasis. The
only known ligand of the c-Met receptor
is hepatocyte growth receptor (HGF).
HGF has been shown to promote the
invasiveness of cancer cells by increasing
matrix adhesion, which encourages the
migration of tumor cells from the point of
origination as well as secretion of cancer
specific enzymes that allow the cancer cells
to break through the basement membrane.
Previous studies have shown CD82 to be
an active metastasis suppressor in normal,
healthy cells. What is not known is how
the loss of CD82 in cancer cells enables
them to metastasize beyond their original
tissue. CD82 is a known metastasize
tumor suppressor in prostate cancer and it
was first identified by Dong et.al. Previous
rat studies have shown that CD82
prevents metastasis but does not affect
tumor formation. In a normal cell CD82
is highly expressed especially in the spleen,
thymus, prostate, lungs, kidneys and other
vital organs. However, in a cancerous cell
CD82 is under-expressed and downregulated which allows the tumor to
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